Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
Go back to Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome| (NASDAQ: QNRX) | Delayed: 7.06 +0.05 (0.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.01 | 52 Week High | $ | |||
| Open | $6.85 | 52 Week Low | $ | |||
| Day High | $7.15 | P/E | N/A | |||
| Day Low | $6.70 | EPS | $ | |||
| Volume | 15,625 | |||||
